The latest report by IMARC Group, titled “mRNA Vaccines and Therapeutics Market Report by Vaccine Type (Self-amplifying mRNA-Based Vaccines, Conventional Non-Amplifying mRNA-Based Vaccines), Treatment Type (Bioengineered Vaccine, Gene Therapy, Gene Transcription, Cell Therapy, Monoclonal Antibody, and Others), Vaccine Manufacturing (In-House, Out-Sourced), Application (Cancer, Infectious Disease, Gene Editing, Protein Replacement), End-User (Hospitals and Clinics, Research Organizations, and Others), and Region 2024-2032“, offers a comprehensive analysis of the industry, which comprises insights on the global mRNA vaccines and therapeutics market report. The global market size reached US$ 57.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 72.7 Billion by 2032, exhibiting a growth rate (CAGR) of 2.53% during 2024-2032.

Factors Affecting the Growth of mRNA Vaccines and Therapeutics Industry:

• Pandemic Response and Urgency for Vaccine Development:

The foremost factor propelling the mRNA vaccines and therapeutics market is the global response to the COVID-19 pandemic. The urgency to develop effective vaccines and therapeutics to combat the spread of the virus has accelerated research and development efforts in the pharmaceutical industry. mRNA technology, with its ability to rapidly produce vaccines, has emerged as a frontrunner in this race against time. The mRNA platform offers advantages such as speed of development, scalability, and versatility, making it an attractive option for addressing emerging infectious diseases. The unprecedented demand for COVID-19 vaccines has driven significant investment and funding into mRNA technology, fostering collaborations between biotech firms, pharmaceutical companies, and governments to expedite vaccine development and manufacturing capabilities. This heightened focus on mRNA vaccines aims to address the current pandemic and also establishes a foundation for future vaccine development against other infectious diseases, thereby driving the growth of the mRNA vaccines and therapeutics market.

• Significant Technological Advancements and Investment in mRNA Research:

Another key factor driving the mRNA vaccines and therapeutics market is the continuous technological advancements and substantial investment in mRNA research and development. Over the past decade, significant progress has been made in optimizing mRNA delivery systems, enhancing stability, and improving immunogenicity, addressing previous challenges associated with mRNA-based therapies. Breakthroughs in lipid nanoparticle formulations for mRNA delivery have notably improved vaccine efficacy and safety profiles, leading to the successful development of mRNA vaccines against COVID-19. Moreover, ongoing research efforts focus on expanding the applications of mRNA technology beyond infectious diseases to areas such as cancer immunotherapy, genetic disorders, and regenerative medicine. The growing understanding of mRNA biology, coupled with substantial investments from both public and private sectors, has propelled innovation in this field, fostering a conducive environment for the growth of the mRNA vaccines and therapeutics market.

• Market Expansion and Commercialization Opportunities:

The increasing recognition of mRNA technology as a viable platform for vaccine and therapeutic development has opened up new market opportunities and commercialization prospects. Pharmaceutical companies and biotech firms are actively expanding their mRNA vaccine and therapeutics portfolios, capitalizing on the versatility of mRNA technology to target a wide range of diseases and medical conditions. Collaborations and partnerships between industry players aim to leverage complementary expertise and resources for the development and commercialization of mRNA-based products. Additionally, regulatory agencies' expedited review processes and emergency use authorizations for mRNA vaccines against COVID-19 have paved the way for accelerated commercialization timelines. As mRNA vaccines gain acceptance and adoption worldwide, there is a growing market demand for mRNA-based therapeutics across diverse therapeutic areas, driving the expansion of the mRNA vaccines and therapeutics market and fostering a competitive landscape conducive to innovation and growth.

Competitive Landscape with Key Player:

• Arcturus Therapeutics Inc.
• BioNTech SE
• CureVac AG
• eTheRNA immunotherapies NV
• ethris GmbH
• GlaxoSmithKline PLC
• Moderna Therapeutics Inc.
• Translate Bio Inc.
• Argos Therapeutics, Inc.
• Sangamo Therapeutics Inc.
• Pfizer Inc.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/mrna-vaccines-therapeutics-market/requestsample

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Vaccine Type:

• Self-amplifying mRNA-Based Vaccines
• Conventional Non-Amplifying mRNA-Based Vaccines

Conventional non-amplifying mRNA-based vaccines dominate the market due to their established safety profiles, scalability in manufacturing, and efficacy demonstrated in combating infectious diseases, including the successful development of COVID-19 vaccines.

Breakup by Treatment Type:

• Bioengineered Vaccine
• Gene Therapy 
• Gene Transcription 
• Cell Therapy
• Monoclonal Antibody
• Others

Bioengineered vaccine holds maximum number of shares due to its efficacy, scalability, and adaptability in rapidly addressing emerging infectious diseases such as COVID-19.

Breakup by Vaccine Manufacturing:

• In-House
• Out-Sourced

In-house manufacturing represents the largest segment due to pharmaceutical companies' desire for greater control over production processes, quality assurance, and supply chain management, ensuring reliability and scalability of mRNA vaccine production.

Breakup by Application:

• Cancer
• Infectious Disease
• Gene Editing
• Protein Replacement

Infectious disease dominates the market due to the urgent global demand for effective vaccines against emerging and re-emerging infectious pathogens, particularly highlighted by the COVID-19 pandemic.

Breakup by End-User:

• Hospitals and Clinics
• Research Organizations
• Others

Hospitals and clinics hold maximum number of shares due to their central role as primary healthcare providers and vaccination centers, where a significant portion of mRNA vaccines and therapeutics are administered and managed.

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Europe’s dominance in the mRNA vaccines and therapeutics market is attributed to its high population density, robust healthcare infrastructure, strong regulatory framework, and widespread adoption of mRNA vaccines and therapeutics, particularly in response to the COVID-19 pandemic.

Global mRNA Vaccines and Therapeutics Market Trends:

The potential for personalized medicine and targeted therapies represents a significant driving force behind the mRNA vaccines and therapeutics market. mRNA technology offers a unique advantage in enabling the development of personalized vaccines and therapies tailored to the genetic makeup and specific medical needs of an individual. This capability holds promise for treating various diseases, including cancer, where traditional treatment approaches often lack specificity and can cause adverse side effects. By harnessing the ability of mRNA to instruct cells to produce therapeutic proteins, researchers can design vaccines and therapies that precisely target disease-causing molecules or antigens, minimizing off-target effects and maximizing efficacy. The prospect of personalized mRNA-based treatments revolutionizes the approach to disease management and also creates opportunities for innovative healthcare solutions, driving growth and investment in the mRNA vaccines and therapeutics market.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163